| Autor: |
HAYASHI, SHIGEN, MIYAZAKI, KUNIHIKO, SHIOZAWA, TOSHIHIRO, OKAUCHI, SHINICHIRO, SAKURAI, HIROFUMI, AKIYAMA, TATSUYA, NOMURA, AKIHIRO, SATOH, HIROAKI, HIZAWA, NOBUYUKI |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Cancer Diagn Progn |
| ISSN: |
2732-7787 |
| DOI: |
10.21873/cdp.10227 |
| Popis: |
Background/Aim: Pemetrexed (PEM) and bevacizumab (BEV) are commonly used in combination as second or subsequent line regimens and maintenance therapy after platinum + PEM + BEV therapy for advanced non-small cell lung cancer (NSCLC). Median progression-free survival (PFS) for PEM + BEV has been reported to be less than six months in both clinical trials and clinical practice, but in clinical practice, we found that some patients demonstrate long-term PFS. Furthermore, there is a paucity of clinical practice data on whether long-term administration of PEM + BEV causes renal dysfunction. This study aimed to clarify these aspects in clinical practice. Patients and Methods: A retrospective review of patients with advanced NSCLC treated with PEM + BEV between September 2011 and June 2022 at four hospitals was conducted. Long-term PFS in PEM + BEV therapy was defined as ≥12 months. Results: During the study period, 109 patients received PEM + BEV treatment. Of them, 42 (38.5%) achieved long-term PFS ≥12 months. No significant differences in patient characteristics were found between patients with PFS ≥12 months and |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
